Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

48
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
48
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

53
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
53
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

41
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
41
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

31
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
31

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter Registry.

Circulation. Genomic and precision medicine·2026
Same author

Natural History of Asymptomatic Phenotypically Mild HCM: Insights From the SHaRe Registry.

Journal of the American College of Cardiology·2026
Same author

Clinical Course and Predictors of Heart Failure in Asymptomatic Obstructive Hypertrophic Cardiomyopathy.

Journal of the American Heart Association·2026
Same author

Influence of Genotype on Cardiac Phenotype in Pediatric Hypertrophic Cardiomyopathy.

Circulation. Genomic and precision medicine·2026
Same author

Multicenter cohort analysis of cardiac amyloidosis patients treated with heart transplant.

Revista espanola de cardiologia (English ed.)·2026
Same author

A translational model of MASLD-associated HFpEF defines mitochondrial dysfunction and cardiac plasticity during disease progression and regression.

Metabolism: clinical and experimental·2026

相关实验视频

Updated: Sep 11, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.7K

过度缩性心肌病变性是一种心肌病变性.

Alessia Argirò1, Victoria Parikh2, Ruxandra Jurcut3,4

  • 1Cardiomyopathy Unit, University of Florence, Florence, Italy.

Nature reviews. Disease primers
|August 14, 2025
PubMed
概括
此摘要是机器生成的。

过度缩性心肌病变 (HCM) 是一种常见的遗传性心脏病,由遗传缺陷引起. 新的向疗法,如肌肉酶抑制剂,正在改善患者的治疗结果和症状.

更多相关视频

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.8K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.5K

相关实验视频

Last Updated: Sep 11, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.7K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.8K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.5K

科学领域:

  • 心脏病学 心脏病学
  • 遗传学 是一个遗传学.
  • 分子医学是分子医学.

背景情况:

  • 增高性心肌病变 (HCM) 是最常见的遗传性心肌病变,是疾病和死亡的重要原因.
  • 这是一种sarcomeric疾病,由sarcomere蛋白质的遗传缺陷引起,导致左心室缩,超收缩性和腹功能障碍.
  • HCM呈现出异质的表型谱,从轻度,稳定的形式到严重的儿童发病病例,导致心力衰竭和心律失常.

研究的目的:

  • 提供超性心肌病的概述,包括其遗传基础,临床表现,诊断方法和不断变化的治疗场景.
  • 突出针对性治疗的最新进展和HCM管理的未来方向.

主要方法:

  • 综述当前关于多变性心肌病遗传学,病理生理学,诊断和治疗的文献.
  • 分析新型治疗药物的疗效和安全性,包括肌抑制剂.
  • 讨论新兴的治疗方式,如基因疗法.

主要成果:

  • 多重成像技术,如回声心电图和心脏MRI对于HCM诊断和预后至关重要.
  • 肌抑制剂在改善HCM患者的功能能力和缓解症状方面已经证明了安全性和有效性.
  • 针对潜在基因变异的基因疗法正在作为创新治疗方法进行研究.

结论:

  • HCM是一种复杂的遗传疾病,具有广泛的临床变异性.
  • 最近的治疗发展,特别是肌抑制剂,为患者提供了显著的改善.
  • 未来的基因治疗研究有望解决HCM的根本原因.